A carregar...
Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells
Many monoclonal antibodies (mAbs) have been extensively used in the clinic, such as rituximab to treat lymphoma. However, resistance and non-responsiveness to mAb treatment have been challenging for this line of therapy. Complement is one of the main mediators of antibody-based cancer therapy via th...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4003131/ https://ncbi.nlm.nih.gov/pubmed/21258360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cmi.2010.35 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|